作者: J. Puig-Barberà , A. Natividad-Sancho , J. Calabuig-Pérez , J.A. Lluch-Rodrigo , E. Pastor-Villalba
DOI: 10.1016/J.VACCINE.2013.05.070
关键词: Retrospective cohort study 、 Medicine 、 Cohort study 、 Hazard ratio 、 Proportional hazards model 、 MF59 、 Internal medicine 、 Comorbidity 、 Trivalent influenza vaccine 、 Comparative effectiveness research 、 Immunology
摘要: Abstract Background Adjuvanted influenza vaccines offer greater and broader immunogenicity to older adults than conventional vaccines. Studies assessing the comparative effectiveness of adjuvanted in this age group are lacking. Methods We conducted a retrospective cohort study estimate MF59-adjuvanted trivalent vaccine (TIV) virosomal-TIV for prevention hospitalization aged ≥65 years. obtained administrative data on immunization status 2010–2011 season. used Cox regression models assess effectiveness; crude adjusted by age, sex, comorbidity, deprivation, type insurance, travel time hospital. accounted clustering at hospital level using multilevel random effects model. Results Overall, 373,798 vaccinated subjects were evaluated. There 40 hospitalizations among 176,618 subjects, contributing 4,288,109 person–weeks risk group, 37 197,180 4,786,360 MF59-TIV group. The hazard ratio (HR) was 0.83 (0.53–1.30), estimated HR relative 0.86 (0.55–1.35). After accounting clustering, associated with 0.94 (0.37–2.38). Conclusion During season, we found no differences years compared those virosomal-TIV.